39 results
SC 14D9/A
PRDS
Pardes Biosciences Inc
17 Aug 23
Tender offer solicitation (amended)
5:09pm
proceeding, stating that “proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise
SC 14D9
PRDS
Pardes Biosciences Inc
28 Jul 23
Tender offer solicitation
5:04pm
in the financial community and otherwise admissible in court” should be considered, and that “[f]air price obviously requires consideration of all relevant
8-K
EX-99.1
PRDS
Pardes Biosciences Inc
3 Apr 23
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
8:00am
therapeutics at this stage of the COVID-19 pandemic, with high levels of underlying population immunity due to vaccination plus ongoing community exposure
424B3
PRDS
Pardes Biosciences Inc
7 Nov 22
Prospectus supplement
4:14pm
candidates may not achieve adequate market acceptance among physicians, patients, third-party payors and others in the medical community necessary … , third-party payors, pharmaceutical companies and others in the medical community. Demonstrating the safety and efficacy of our product candidates
424B3
sksw0828xki9r je4
15 Aug 22
Prospectus supplement
5:41pm
424B3
hig nfrlp14lrqar2lmh
10 May 22
Prospectus supplement
4:35pm
DEF 14A
of0rafdr v95ka3z4
26 Apr 22
Definitive proxy
6:07am
424B3
whjsf
1 Apr 22
Prospectus supplement
4:01pm
POS AM
yi6s8apfwcgr 76
30 Mar 22
Prospectus update (post-effective amendment)
7:32am
10-K
EX-10.18
hfibwpbo 1iiczyqj
29 Mar 22
Annual report
5:29pm
10-K
pp5m aaugvqitai5t0lc
29 Mar 22
Annual report
5:29pm
8-K
7hdafh45jjk7jxknv8
9 Mar 22
Regulation FD Disclosure
11:12am
8-K
du50v9re9yhmska9ivn
14 Feb 22
Regulation FD Disclosure
7:26am
424B3
yeha jx3h
1 Feb 22
Prospectus supplement
5:03pm